News & Events
-
July 23, 2015
CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia
July 23, 2015 CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia Austin, TX – 23 July 2015 – The Clinical Data Interchange Standards Consortium (CDISC), the Critical Path Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data standards for clinical research in the areas of Schizophrenia, Hepatitis C...... -
July 21, 2015
Critical Path Institute Establishes The Global Pediatric Clinical Trials Network Pre-Launch Consortium
July 22, 2015 Critical Path Institute Establishes The Global Pediatric Clinical Trials Network Pre-Launch Consortium The Pre-Launch Consortium aims to establish the first global, multi-specialty clinical trials network dedicated to the timely and efficient development of safe and effective therapies for children. TUCSON, Ariz., July 22, 2015 — The Critical Path Institute (C-Path),...... -
May 19, 2015
Critical Path Institute Launches New Neonatal Consortium
May 19, 2015 Critical Path Institute Launches New Neonatal Consortium The International Neonatal Consortium (INC) aims to accelerate the development of safe, effective therapies for newborns. TUCSON, Ariz., May 19, 2015 — Today, the Critical Path Institute (C-Path), a pioneering non-profit organization dedicated to accelerating the pace and reducing the costs of medical product development...... -
April 27, 2015
Critical Path Institute Secures Regulatory Support For Parkinson’s And Alzheimer’s Disease Biomarkers
April 27, 2015 Critical Path Institute Secures Regulatory Support For Parkinson’s And Alzheimer’s Disease Biomarkers FDA Endorses Biomarkers for Use in Early Stages of Brain Disease TUCSON, Ariz., April 27, 2015 — Critical Path Institute (C-Path) announced that the U.S. Food and Drug Administration (FDA) has issued three Letters of Support to C-Path’s Coalition Against...... -
February 6, 2015
European Medicines Agency Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development
February 6, 2015 European Medicines Agency Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development Provides major boost for improved development of TB treatment to meet major public health challenge TUCSON, Ariz., February 6, 2015 – The Critical Path Institute (C-Path), an independent, nonprofit organization working to accelerate the process of drug and medical product development, announced......